These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1001 related articles for article (PubMed ID: 25716100)
1. Targeting breast cancer with CDK inhibitors. Mayer EL Curr Oncol Rep; 2015; 17(5):443. PubMed ID: 25716100 [TBL] [Abstract][Full Text] [Related]
2. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib. Kwapisz D Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274 [TBL] [Abstract][Full Text] [Related]
3. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women. Cersosimo RJ Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120 [TBL] [Abstract][Full Text] [Related]
4. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations. Spring LM; Zangardi ML; Moy B; Bardia A Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010 [TBL] [Abstract][Full Text] [Related]
5. CDK4-6 inhibitors in breast cancer: current status and future development. Choo JR; Lee SC Expert Opin Drug Metab Toxicol; 2018 Nov; 14(11):1123-1138. PubMed ID: 30360668 [TBL] [Abstract][Full Text] [Related]
6. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer. Bilgin B; Sendur MAN; Şener Dede D; Akıncı MB; Yalçın B Curr Med Res Opin; 2017 Sep; 33(9):1559-1569. PubMed ID: 28657360 [TBL] [Abstract][Full Text] [Related]
7. CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib. Eggersmann TK; Degenhardt T; Gluz O; Wuerstlein R; Harbeck N BioDrugs; 2019 Apr; 33(2):125-135. PubMed ID: 30847853 [TBL] [Abstract][Full Text] [Related]
8. CDK4/6 blockade in breast cancer: current experience and future perspectives. Zardavas D; Pondé N; Tryfonidis K Expert Opin Investig Drugs; 2017 Dec; 26(12):1357-1372. PubMed ID: 29027483 [TBL] [Abstract][Full Text] [Related]
9. Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials. Ramos-Esquivel A; Hernández-Steller H; Savard MF; Landaverde DU Breast Cancer; 2018 Jul; 25(4):479-488. PubMed ID: 29470723 [TBL] [Abstract][Full Text] [Related]
10. Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data. Vidula N; Rugo HS Clin Breast Cancer; 2016 Feb; 16(1):8-17. PubMed ID: 26303211 [TBL] [Abstract][Full Text] [Related]
11. Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies. Kwapisz D Breast Cancer; 2018 Sep; 25(5):506-516. PubMed ID: 29700711 [TBL] [Abstract][Full Text] [Related]
12. The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer. Shah AN; Cristofanilli M Curr Treat Options Oncol; 2017 Jan; 18(1):6. PubMed ID: 28197838 [TBL] [Abstract][Full Text] [Related]
13. [Cell cycle inhibitors in endocrine receptor positive breast cancer]. Sablin MP; Ricci F; Loirat D; Jobard A; Basse C; Romano E; Le Tourneau C; Dieras V Bull Cancer; 2017 Feb; 104(2):114-122. PubMed ID: 28126188 [TBL] [Abstract][Full Text] [Related]
14. The Role of CDK4/6 Inhibition in Breast Cancer. Murphy CG; Dickler MN Oncologist; 2015 May; 20(5):483-90. PubMed ID: 25876993 [TBL] [Abstract][Full Text] [Related]
15. Mechanisms of therapeutic CDK4/6 inhibition in breast cancer. Scott SC; Lee SS; Abraham J Semin Oncol; 2017 Dec; 44(6):385-394. PubMed ID: 29935900 [TBL] [Abstract][Full Text] [Related]
16. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells. Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163 [TBL] [Abstract][Full Text] [Related]
17. Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer. Tamura K Jpn J Clin Oncol; 2019 Dec; 49(11):993-998. PubMed ID: 31665472 [TBL] [Abstract][Full Text] [Related]
18. Review of Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer. Hecht KA; Selby C Ann Pharmacother; 2019 Feb; 53(2):195-203. PubMed ID: 30079740 [TBL] [Abstract][Full Text] [Related]
19. Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions. Spring L; Bardia A; Modi S Discov Med; 2016 Jan; 21(113):65-74. PubMed ID: 26896604 [TBL] [Abstract][Full Text] [Related]
20. Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment. Parylo S; Vennepureddy A; Dhar V; Patibandla P; Sokoloff A J Oncol Pharm Pract; 2019 Jan; 25(1):110-129. PubMed ID: 29726787 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]